193 related articles for article (PubMed ID: 27314282)
1. CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.
Dai W; Miao H; Fang S; Fang T; Chen N; Li M
Mol Med Rep; 2016 Aug; 14(2):1509-14. PubMed ID: 27314282
[TBL] [Abstract][Full Text] [Related]
2. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF
Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Xing C; Xie H; Zhou L; Zhou W; Zhang W; Ding S; Wei B; Yu X; Su R; Zheng S
Biochem Biophys Res Commun; 2012 Mar; 420(1):29-35. PubMed ID: 22390936
[TBL] [Abstract][Full Text] [Related]
4. CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer.
Barrón EV; Roman-Bassaure E; Sánchez-Sandoval AL; Espinosa AM; Guardado-Estrada M; Medina I; Juárez E; Alfaro A; Bermúdez M; Zamora R; García-Ruiz C; Gomora JC; Kofman S; Pérez-Armendariz EM; Berumen J
PLoS One; 2015; 10(9):e0137397. PubMed ID: 26372210
[TBL] [Abstract][Full Text] [Related]
5. CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.
Zhang LP; Li WJ; Zhu YF; Huang SY; Fang SY; Shen L; Gao YL
Int J Clin Exp Pathol; 2015; 8(5):4535-44. PubMed ID: 26191143
[TBL] [Abstract][Full Text] [Related]
6. Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
Wang X; Han L; Zhang J; Xia Q
Dig Dis Sci; 2015 Oct; 60(10):3011-8. PubMed ID: 26055238
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-Dependent Kinase Inhibitor 3 Promotes Cancer Cell Proliferation and Tumorigenesis in Nasopharyngeal Carcinoma by Targeting p27.
Wang H; Chen H; Zhou H; Yu W; Lu Z
Oncol Res; 2017 Nov; 25(9):1431-1440. PubMed ID: 28109073
[TBL] [Abstract][Full Text] [Related]
8. CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1.
Li WH; Zhang L; Wu YH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3614-3623. PubMed ID: 32329836
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-related receptor γ is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27.
Kim JH; Choi YK; Byun JK; Kim MK; Kang YN; Kim SH; Lee S; Jang BK; Park KG
Exp Mol Med; 2016 Mar; 48(3):e213. PubMed ID: 26940882
[TBL] [Abstract][Full Text] [Related]
10. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
11. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway.
Liu D; Zhang J; Wu Y; Shi G; Yuan H; Lu Z; Zhu Q; Wu P; Lu C; Guo F; Chen J; Jiang K; Miao Y
Int J Cancer; 2018 Apr; 142(7):1392-1404. PubMed ID: 29168185
[TBL] [Abstract][Full Text] [Related]
12. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Wang L; Sun L; Huang J; Jiang M
Cell Prolif; 2011 Jun; 44(3):291-9. PubMed ID: 21535270
[TBL] [Abstract][Full Text] [Related]
14. CDKN3 expression predicates poor prognosis and regulates adriamycin sensitivity in hepatocellular carcinoma
Dai W; Fang S; Cai G; Dai J; Lin G; Ye Q; Miao H; Chen M; Tan X; Chen N; Liu X; Li M
J Int Med Res; 2020 Jul; 48(7):300060520936879. PubMed ID: 32721244
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Li Y; Ji S; Fu LY; Jiang T; Wu D; Meng FD
Oncol Res; 2017 May; 25(5):721-731. PubMed ID: 27983933
[TBL] [Abstract][Full Text] [Related]
16. Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53.
Liu J; Rao J; Lou X; Zhai J; Ni Z; Wang X
Cell Physiol Biochem; 2017; 44(1):255-266. PubMed ID: 29190611
[TBL] [Abstract][Full Text] [Related]
17. Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Deng M; Wang J; Chen Y; Zhang L; Xie G; Liu Q; Zhang T; Yuan P; Liu D
Mol Med Rep; 2016 Aug; 14(2):1523-30. PubMed ID: 27314680
[TBL] [Abstract][Full Text] [Related]
18. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
Fornari F; Milazzo M; Chieco P; Negrini M; Marasco E; Capranico G; Mantovani V; Marinello J; Sabbioni S; Callegari E; Cescon M; Ravaioli M; Croce CM; Bolondi L; Gramantieri L
J Pathol; 2012 Jul; 227(3):275-85. PubMed ID: 22262409
[TBL] [Abstract][Full Text] [Related]
19. The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2.
Lai WL; Hung WY; Wong LL; Zhou Y; Leong VY; Lee JM; Ng IO; Jin DY; Ching YP
Hepatology; 2012 Nov; 56(5):1770-81. PubMed ID: 22610972
[TBL] [Abstract][Full Text] [Related]
20. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
Li T; Xue H; Guo Y; Guo K
Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
